Emergent BioSolutions announces investments in manufacturing capability

GAITHERSBURG, Md. — Emergent BioSolutions announced on Feb. 14, 2006, that the Michigan Economic Development Corp. has granted BioPort Corp.’s application for financial incentives associated with a planned investment of $75 million in a manufacturing facility at its location in Lansing, Mich.

BioPort is a subsidiary of Emergent BioSolutions.

This incentive package is similar to one the company received in late 2004 from the state of Maryland for the expansion of product development and manufacturing capacity at a 150,000-square-foot facility in Frederick, Md.

The Lansing expansion project, once completed, is designed to allow the company to produce up to 80 million doses per year of its anthrax vaccine BioThrax.

The company’s plant in Frederick is to be used for future vaccine manufacturing capacity. Emergent BioSolutions has designed it to produce multiple vaccine products and employ 300 to 400 people when operating at full capacity.

Emergent BioSolutions holds rights to acquire an additional facility of equal size at the same site to further support its growth plans. The company currently maintains its corporate headquarters and product development operations in Gaithersburg, Maryland.